Former Sanofi chief Christopher Viehbacher joins PureTech

27 February 2015

The former chief executive of French pharma major Sanofi (Euronext: SAN) Christopher Viehbacher has been appointed to the board of directors of US R&D company PureTech.

Robert Langer, PureTech co-founder and senior partner, said: “It's has been a pleasure to know Chris for many years and I am very excited that we will be working together more closely now. The PureTech Board is delighted to have him join us and to have access to his insights as our pipeline advances toward commercialization."

Mr Viehbacher left Sanofi in October. He was also the Chairman of the Board of Genzyme in Boston. Prior to joining Sanofi, Mr Viehbacher spent 20 years with GlaxoSmithKline (LSE: GSK) ultimately as President of GSK's North American pharmaceutical division.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK